Personal information

Other IDs

Scopus Author ID: 7402229941
Loop profile: 862131

Activities

Collapse all

Employment (3)

GSK plc: Stevenage, Herfordhsire, GB

2023-01-04 to present | Senior Vice President and Head (Oncology Translational Research Org)
Employment
Source: Self-asserted source
Tony Ng

King's College London: London, GB

2017-08-01 to present | Director/Head (Comprehensive Cancer Centre)
Employment
Source: Self-asserted source
Tony Ng

King's College London: London, GB

2004-11-01 to present | Richard Dimbleby Professor of Cancer Research (Richard Dimbleby Department of Cancer Research)
Employment
Source: Self-asserted source
Tony Ng

Education and qualifications (3)

The Royal College of Pathologists: London, London, GB

2003-08-29 to present | FRCPath (Immunopathology)
Qualification
Source: Self-asserted source
Tony Ng

Medical College of St. Bartholomew’s Hospital, University of London: London, GB

1994-08-29 to 1997-08-28 | PhD (Immunology)
Education
Source: Self-asserted source
Tony Ng

University of Aberdeen: Aberdeen, Aberdeen, GB

1984-09-01 to 1989-08-31 | MB ChB (Medicine and Surgery)
Education
Source: Self-asserted source
Tony Ng

Professional activities (2)

European Academy of Cancer Sciences: Brussels, BE

2017-08-01 to present | Fellow of the European Academy of Cancer Sciences
Invited position
Source: Self-asserted source
Tony Ng

Academy of Medical Sciences: London, GB

2013-08-30 to present | FMedSci (Imaging)
Invited position
Source: Self-asserted source
Tony Ng

Funding (11)

Integrated multi-modal tissue state mapping of TNBC progression

2021-09 to 2024-08 | Grant
Wellcome Leap ( Los Angeles, US)
Source: Self-asserted source
Tony Ng

GSK - KCL Translational Oncology Research Hub

2021-08 to 2026-08 | Contract
GSK ( Collegeville, Pennsylania, US)
GRANT_NUMBER:

300003706
Source: Self-asserted source
Tony Ng

Multimodality Early Detection of Head and Neck Cancer Recurrence

2021-03 to 2026-02 | Grant
Cancer Research UK (London, GB)
Source: Self-asserted source
Tony Ng

Next generation molecular imaging and therapy with radionuclides

2019-10 to 2024-09 | Grant
Engineering and Physical Sciences Research Council (Swindon, GB)
Source: Self-asserted source
Tony Ng

A multiuser radioanalytical facility for molecular imaging and radiouclide therapy re-search.

2019-07 to 2024-06 | Grant
Wellcome Trust (London, GB)
Source: Self-asserted source
Tony Ng

CRUK: Improving the early detection of lung cancer by combining exosomal analysis of hypoxia with standard of care imaging

2019-03 to 2024-02 | Grant
Cancer Research UK (London, GB)
Source: Self-asserted source
Tony Ng

H2020-JTI-IMI2-2017-13. Integrated IMMUnoprofiling of large adaptive CANcer patients cohorts.

2019-03 to 2024-02 | Grant
European Commission (Brussels, BE)
Source: Self-asserted source
Tony Ng

NCITA - National Cancer Imaging Translational Accelerator C1519/28682 (Cambridge/ICR/Imperial College London/KCL/Oxford/UCL).

2018-09 to 2023-08 | Grant
Cancer Research UK (London, GB)
Source: Self-asserted source
Tony Ng

UCL-Barts-King’s-Crick CRUK Major Centre (City of London Cancer Centre). A CRUK Centre of Excellence in Biotherapeutics.

2018-04 to 2023-03 | Grant
Cancer Research UK (London, GB)
Source: Self-asserted source
Tony Ng

KHP Experimental Cancer Medicine Centre

2017-04 to 2022-03 | Grant
Cancer Research UK (London, GB)
Source: Self-asserted source
Tony Ng

King’s Health Partners Comprehensive Cancer Centre

2017-04 to 2022-03 | Grant
Cancer Research UK (London, GB)
Source: Self-asserted source
Tony Ng

Peer review (2 reviews for 2 publications/grants)

Review activity for Cancer immunology and immunotherapy. (1)
Review activity for EMBO molecular medicine. (1)
How many people are using ORCID?